Schizophrenia Research
Volume 98, Issue 1 , Pages 8-15 , January 2008

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia

  • C. Daniel Mullins

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 410 706 0879; fax: +1 410 706 5394.
    • ,
  • Nour A. Obeidat

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • ,
  • Brian J. Cuffel

      Affiliations

    • Pfizer Inc, New York NY, United States
    • ,
  • John Naradzay

      Affiliations

    • University of Maryland School of Pharmacy, 220 Arch Street, Baltimore, MD 21201, United States
    • ,
  • Antony D. Loebel

      Affiliations

    • Pfizer Inc, New York NY, United States

Received 15 November 2006 ,Revised 25 April 2007 ,Accepted 26 April 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0920-9964(07)00191-0

doi: 10.1016/j.schres.2007.04.035

Schizophrenia Research
Volume 98, Issue 1 , Pages 8-15 , January 2008

Article Tools

* Image Usage & Resolution